Navigation Links
Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc
Date:12/10/2013

AUSTIN, Texas, Dec. 10, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. The company also received Fast Track designation for AeroVanc pursuant to section 506(a)(1) of the Food and Drug Administration Safety and Innovation Act (FDASIA).

The QIDP and Fast Track designation provide AeroVanc access to certain incentives, including priority review associated with a New Drug Application (NDA) submission and an additional five years of exclusivity under the Hatch-Waxman Act upon FDA approval of AeroVanc. Last year AeroVanc received orphan designation, which provides the product seven years of market exclusivity, and various other incentives. 

"The recent QIDP status forms an important part of our market exclusivity strategy," says Rob Neville, CEO of Savara Pharmaceuticals. "This designation along with Orphan Drug status, our formulation patent protection and our inhalation device exclusivity creates a very robust protection from competition."

Savara Pharmaceuticals is currently conducting a nationwide Phase II clinical trial evaluating the safety and efficacy of AeroVanc in CF patients. For more information, please visit http://www.aerovanc.com.  

About AeroVanc
Vancomycin is an FDA-approved intravenously administered antibiotic with proven efficacy in the treatment of MRSA infections. AeroVanc is an investigational, proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. AeroVanc is currently being developed as a treatment for persistent MRSA lung infection in CF patients. By delivering vancomycin directly to the lungs, higher vancomycin concentrations are achieved at the site of infection, which is expected to lead to improved clinical efficacy. In addition, direct delivery of the drug into the lungs reduces exposure to the drug elsewhere in the body, and is thereby expected to reduce the risk of systemic drug-related side effects.

About Savara Pharmaceuticals
Savara Pharmaceuticals is a specialty pharmaceutical company developing AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis. For more information, please see Savara's website at www.savarapharma.com, or www.aerovanc.com, or find us on Twitter, Facebook and LinkedIn.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors
2. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
3. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
4. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
8. Neuraltus Pharmaceuticals NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND
9. Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
10. Actinium Pharmaceuticals Announces Clinical Advisory Board Meeting At The 2013 ASH Conference
11. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... FREMONT, Calif. , July 13, 2017 RK ... (CA) Board of Pharmacy certification for its Fremont, ... chain support solutions in the Tri-Valley and San ... The City of Fremont , with its ... Logistics Group to provide such a powerful resource to the ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
(Date:7/10/2017)... 10, 2017  US medical equipment and supply demand ... to Medical Equipment & Supplies: United States ... Reports. Continued increases in demand for medical services – ... population and supported by gains in disposable personal income ... New product introductions will also drive sales as providers ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... 2017 , ... There’s a lot of confusing lingo out there surrounding spinal ... thing. But it’s crucial to understand both the differences and similarities between these two ... MD, PhD, founder and president of Atlantic Spine Center . , The ...
(Date:7/20/2017)... ... 2017 , ... A budget proposal to switch to an alternate consumer price ... (COLA) is a bad deal for older and disabled Americans, says The Senior ... even more slowly than the conventional one that is currently used to determine the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Dr. Jig Patel is pleased to announce ... or without a referral. Understanding the difficulties that face people who are missing ... this permanent alternative to removable dentures and bridges. Not only does an implant improve ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... a $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral ... special health care needs in rural and underserved areas. , The Predoctoral Pediatric ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... “surprising habits” that may sometimes lead to, or worsen, varicose veins in some ... Center notes that, while avoiding certain not-so-good practices, like excessive sitting or standing, ...
Breaking Medicine News(10 mins):